IsoPlexis — Merger or Acquisition (December 2022)
10 slides from IsoPlexis's merger presentation, Dec 23, 2022
Slide 1: Berkeley Lights Town Hall
Berkeley Lights Town Hall Strictly Private & Confidential December 22, 2022
Slide 2: Forward-Looking Statements
Forward-Looking Statements Certain statements in this communication regarding the proposed transaction between Berkeley Lights and IsoPlexis, the expected timetable for completing the transaction, benefits and synergies of the transaction, future opportunities for the combined company and products a
Slide 3: A Transformational Combination
A Transformational Combination Most comprehensive technology portfolio to isolate, manipulate, and characterize live cells (Nasdaq: CELL) A FUNCTIONAL CELL BIOLOGY COMPANY LIVE CELL, FUNCTIONAL BIOLOGY DEEP PROFILING OF SINGLE CELLS The only single-cell platform enabling functional proteomics + 3 Ne
Slide 4: PhenomeX: The Functional Cell Biology Company
PhenomeX: The Functional Cell Biology Company WHAT WE DO Enable scientists to unlock the potential of cell biology for research and clinical applications HOW WE DO IT By providing a deeper analysis of cell function while preserving the live cells of interest WHY IT MATTERS Because understanding the
Slide 5: IsoPlexis at a Glance
IsoPlexis at a Glance 5 Highly Multiplexed Proteomic Barcoding 2. Single-cell capture 3. Highly multiplexed proteomic detection 1. Sample loaded onto chip 30+ Proteins Per Cell Rapidly Growing Installed Base Installed Base (Total Instruments) ‘21 ‘22 Accelerating the fight against our toughest disea
Slide 6: Accelerates Progress Across Every Pillar of Berkeley Lights' Strategic Plan
Accelerates Progress Across Every Pillar of Berkeley Lights’ Strategic Plan 6 Building a world-class team Prioritizing R&D return on investment Delivering consistent commercial execution Led by Berkeley Lights’ experienced Board of Directors Enhances a proven management team highly experienced in co
Slide 7: Accelerates Progress Across Every Pillar of Berkeley Lights' Strategic Plan (continued)
7 Participating in a larger cell biology market with a wide range of tools and services through cross-selling opportunities to existing and new customers Enabling significant productivity through combined R&D, G&A and supply chain / manufacturing infrastructure Evaluating M&A opportunities that will
Slide 8: Confidentiality Reminder: ISO and BLI still operating independently
ISO and BLI are still operating independently All work associated with diligence and integration is CONFIDENTIAL Due diligence materials and work shall not be shared outside of BLI’s due diligence team Integration planning work shall not be shared outside of the integration planning team BLI’s integ
Slide 9: A Functional Cell Biology Company
A FUNCTIONAL CELL BIOLOGY COMPANY
Slide 10: Q&A Session
Q&A Session Strictly Private & Confidential